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Abstract: In the past two decades, more than 20 viruses with selective tropism for tumor cells 
have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of 
these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So 
far, nine phase I or II clinical trials have been conducted or initiated using four different types 
of OVs in patients with recurrent ovarian cancers. In this article, we summarize the different 
OVs that are being assessed as therapeutics for ovarian cancer. We also present an overview 
of recent advances in identification of key genetic or immune-response pathways involved in 
tumorigenesis of ovarian cancer, which provides a better understanding of the tumor specifici-
ties and oncolytic properties of OVs. In addition, we discuss how next-generation OVs could 
be genetically modified or integrated into multimodality regimens to improve clinical outcomes 
based on recent advances in ovarian cancer biology.
Keywords: oncolytic virus, virotherapy, ovarian cancer, preclinical studies, clinical trial
Introduction
Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the 
gynecologic malignancies.1,2 If caught at an early stage, the majority (approximately 90%) 
of ovarian cancer patients are cured. Approximately 90% of ovarian tumors are epithelial 
in origin, with the remainder being sex cord–stromal and germ cell tumors. These latter, 
rarer tumor types of the ovary and epithelial tumors that are confined to one or both 
ovaries (ie, stage 1A/B) are usually treated with surgery alone due to the early diagnosis 
and lower metastatic potential. Over three-quarters of ovarian tumors, however, are 
discovered at an advanced metastatic stage, when prognosis is poor.
Most other carcinomas follow a pathway of disease dissemination that involves 
intravasation into the bloodstream followed by extravasation at distant tissue sites, as 
well involvement of lymphatic spread.3 Metastasis of epithelial ovarian cancer is unique 
in that it typically spreads by direct dissemination or shedding of cancer cells from 
the primary tumor site into the ascites of the peritoneal space, followed by secondary 
tumor seeding by implantation onto the serosal surfaces of abdominal organs.4,5 This 
implies that there are likely molecular and cellular properties of ovarian tumor cells that 
dictate this pattern of metastasis; unique properties, perhaps, that could be exploited 
for more efficacious therapeutic strategies.
Heterogeneity of ovarian cancer
Epithelial ovarian cancer does not represent a single disease, but rather can be 
distinguished and characterized as distinct histological subtypes.6 The four most 
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common histotypes of epithelial ovarian cancer are serous, 
endometrioid, clear cell, and mucinous; these can also be 
subclassified based on grade, although clear cell is always 
considered high-grade. Further to this complexity, a sub-
stantial proportion of epithelial ovarian cancer cases will be 
of mixed histologies.
Over the last several years, genetics, genomics, and 
gene-expression analyses have demonstrated that there are 
common mutations and aberrant signaling pathways that 
typify these histologic subtypes. High-grade serous ovarian 
cancers almost universally harbor mutations in TP53, and 
these tumor cells are defined as being highly genomically 
unstable.7,8 In comparison, TP53 mutations and genomic 
instability are rare in low-grade serous ovarian cancers, 
but rather these tumor types commonly possess activating 
mutations in KRAS and BRAF. Gene-expression analyses 
have corroborated clinicopathologic definitions of these 
histologic subtypes, since each subtype has a characteristic 
gene-expression pattern resembling the normal cell/tissue 
type.9 Serous ovarian cancer is similar to fallopian tube 
epithelium, endometrioid, and clear cell to endometrial 
cells, and mucinous to gastrointestinal cells of the colon. 
This also reflects the argument that a subset of these ovarian 
malignancies may arise from origins alternative to the ovary. 
For example, a substantial amount of strong evidence directs 
the putative source of high-grade serous ovarian cancer in 
the secretory epithelial cells of fallopian tube fimbriae.10 
Endometriosis, a common pathologic condition seen in 
approximately 15% of all women, is also a potential source 
for endometrioid and clear cell cancers of the ovary.11 This 
heterogeneity in tumor types seen in epithelial ovarian 
cancer is clinically relevant, since it is well established that 
tumor aggressiveness, response to chemotherapy, and patient 
prognosis are correlated with tumor type.2 There is a trend 
towards rationally selecting patients for clinical trials using 
targeted therapeutics based on ovarian cancer histologic 
subtype;12 however, the majority of ovarian cancer patients 
with metastatic disease are treated with the standard regimen 
of combined carboplatin and paclitaxel. It remains to be seen 
if ovarian cancer will be a cancer type that can reap further 
benefits of personalized medicine through the targeting 
of histologic subtypes with their underlying genetic and 
biochemical defects.
Ovarian cancer–initiating cells
The cancer-initiating cell (CIC) theory maintains that a 
minority of cells within a primary tumor have the unique 
capacity to repopulate a heterogeneous tumor as well as 
self-renew.13 CICs are believed to commonly have a low 
mitotic rate as well as express factors that can promote their 
survival. Given this, CICs demonstrate resistance to chemo- 
and radiotherapy, thus serving as a potential source for 
cancer recurrence, since current chemotherapies commonly 
fail to eliminate CICs.14 CICs were originally defined within 
hematologic malignancies, but they have been identified in 
many different solid cancers over the past decade, including 
breast,15 prostate,16 colon,17,18 liver,19 pancreatic,20 brain,21 
melanoma,22 and ovarian.23–25
Ovarian CICs (OCICs) have been identified by several 
groups and have been isolated and characterized using a 
diverse set of markers and activities. Szotek and colleagues 
successfully isolated OCICs in mouse ovarian tumor cells 
and from human ovarian cancer cell lines and patient ascites 
by verapamil-sensitive Hoechst efflux side population (SP).24 
Fitting the definition of CICs, the SP cells represented , 1% 
of the origin population of cells, had more robust sphere-
forming and tumour-forming potential than non-SP cells, and 
repopulated a heterogeneous tumor of both SP and non-SP 
cells. Subsequent to this first report, other groups have 
selected OCICs from human ovarian tumors by sorting for 
cell surface coexpression of CD44+ and CD117+,25 CD44+ and 
MyD88+,26 or CD133+ and CD117+,27 although enrichment for 
stem-like cells has also been performed using CD133+28,29 or 
CD24+30 alone. More recently, groups have demonstrated that 
aldehyde dehydrogenase activity can define an OCIC popula-
tion in combination with CD13331,32 or CD44.33 A recent study 
tested 150 combinations of eight cancer stem cell markers 
and found that the combination of three – CD44, CD24, and 
epithelial cell adhesion molecule – exhibited the most robust 
enrichment of OCICs.34 Importantly, the OCICs that have 
been identified by these different methods are commonly less 
sensitive to standard chemotherapeutics used to treat ovarian 
cancer patients.26 Thus, if these cells are the main contribu-
tors to recurrence of resistant disease, then therapeutics that 
are more efficacious at targeting and killing these progenitor 
cells are of utmost importance.
immune response in ovarian cancer
It is important to recognize and appreciate the antitumor 
immune response and subsequent immune evasion by 
late-stage metastatic cancers as a universal hallmark of 
malignancy.35,36 The immune system is thought to play an 
essential role in facilitating tumor regression in response to 
chemotherapy for ovarian cancer. The presence of tumor-
infiltrating lymphocytes in response to chemotherapy and 
even before chemotherapy is initiated is associated with 






better prognosis for ovarian cancer patients.37,38 There have 
been numerous activities to generate anticancer vaccines for 
ovarian cancer,39 yet none have come to fruition. Interestingly, 
a recent report has targeted OCICs via fusion with dendritic 
cells as being a potential means for immunotherapy for 
ovarian cancer.40,41
Late-stage ovarian tumors are believed to grow in an 
immunosuppressive environment, with many key cytokines 
known to stimulate an antitumor response being significantly 
reduced in the hostile ascites environment during metastatic 
disease progression.42 For example, transforming growth 
factor-beta, which is a potent immunosuppressive factor 
known to promote late-stage human cancer progression,43 
is present in biologically relevant quantities in malignant 
ascites.44,45 Taken together, it implies that recruiting an active 
immune response is likely a critical component to effective 
therapy for ovarian cancer; however, significant pathobio-
logical hurdles would still have to be overcome.
Preclinical studies with oncolytic 
viruses in ovarian cancer
Debulking surgery followed by chemotherapy using a 
 platinum/taxane-based regimen is the current standard of care 
for ovarian cancer. However, more than 65% of patients will 
eventually relapse.46 The overall 5-year survival rate for all 
stages of ovarian cancer is currently less than 50%, and for 
advanced ovarian cancer remains 15%–30%.1 New, more 
effective therapeutic approaches for treatment of recurrent or 
drug-resistant ovarian cancer remain an urgent unmet medi-
cal need. The emerging oncolytic virotherapy represents a 
unique strategy and holds great promise for cancer therapy. 
Oncolytic virotherapy is defined as the use of a class of non- 
or low-pathogenic viruses that is able to preferably replicate 
in cancer cells and eliminate them in situ; for example, via 
direct lysis or induction of apoptosis.47 Currently exploited 
oncolytic viruses (OVs) are either naturally occurring viruses 
(either human or nonhuman) that have little or no natural 
pathogenicity in humans, including reovirus, myxoma virus 
(MYXV), vaccinia virus (VV), measles virus (MV), vesicular 
stomatitis virus (VSV), sindbis virus (SV), Maraba virus 
(MRB), and echovirus type 1 (EV1), or comprise genetically 
engineered viruses, including adenoviruses (Ads), herpes 
simplex viruses (HSVs) or certain poxviruses. The OVs 
that are currently being developed to treat ovarian cancer 
are summarized in Table 1. Most recently, two related 
reviews on OVs for ovarian cancer have been published, one 
review outlining the current status of the clinical data from 
human trials and the other focusing on OVs for gynecologic 
malignancies.48,49 In this review, we attempt to provide more 
comprehensive and up-to-date summaries of the molecular 
biology of ovarian cancer and the results from preclinical 
and clinical studies using OVs for ovarian cancer.
General mechanisms of tumor  
selectivity of OVs
The development of malignancies, namely tumorigenesis, can 
be seen as an evolution of normal cells to acquire the capacity 
for uncontrolled cell division and invasive capabilities that 
mediate dissemination into normal organs and tissues. Dur-
ing this process, tumor cells acquire genetic mutations and 
cellular changes that progressively interfere with tumor 
cell recognition and clearance by host immune pathways. 
Coincidentally, these cellular and genetic changes of the 
tumor cells over normal cells also provide the molecular tar-
gets for OVs to selectively infect and replicate in tumor cells. 
There are at least five general mechanisms that determine 
the tumor selectivity of OVs.
Defective innate immune responses of tumor cells
The most important inducible innate antiviral defense system 
in normal cells is the interferon (IFN) signaling pathway. In 
normal somatic cells, virus invasion can be sensed by a vari-
ety of sentinel receptors, such as membrane-bound Toll-like 
receptors or cytoplasmic sensors like the nucleic acid helicases 
encoded by retinoic-acid inducible gene-I, melanoma differ-
entiation associated gene 5, and DNA-dependent activator of 
IFN regulatory factors.50 Viral infections trigger these sensor 
proteins to initiate signaling cascades that trigger IFN induc-
tion and secretion from most nontransformed mammalian 
cells. Secreted type I IFN then acts on both virus-infected and 
uninfected cells to upregulate the expression of many antiviral 
proteins. Over 200 such IFN-inducible host proteins have 
been described, including members whose primary function 
is to intercept the virus infection.51 One example of such an 
IFN-induced antiviral protein is protein kinase R (PKR). Once 
induced, PKR can then be activated by virus-derived dsRNA. 
Upon activation, PKR phosphorylates and inactivates eukary-
otic initiation factor 2 alpha (eIF2α), causing global inhibition 
of protein synthesis of both host and viral proteins.51 IFN also 
has tumor-suppression properties that are also mediated by 
PKR and other IFN-stimulated proteins. Genetic defects in 
the cellular IFN-response pathway, as well as other related 
innate immune responses (eg, TNF induction, apoptosis, etc) 
are also frequently seen in cancer cells, and these acquired sig-
naling defects may in fact be crucial for the proliferation and 
immune evasion of cancer cells.52,53 An indirect  consequence 
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of these cellular defects is to frequently convert cancer cells 
to be more permissive to infection by a spectrum of OVs 
that are typically more efficiently suppressed in normal 
somatic cells. For example, one of the common mutations 
leading to inhibition of the IFN signaling response pathway 
is constitutive Ras activation caused by various mutations to 
this cellular oncogene (present in approximately 30% of all 
human cancers).54 Activated Ras signaling also inhibits PKR, 
likely through dephosphorylation of PKR, and this in turn 
promotes infection and oncolysis of Ras-activated cancer 
cells by reovirus.55
Overexpression of viral receptors on tumor cells
Many cancer-specific mutations result in elevated expression 
of certain cell surface molecules that facilitate tumorigenesis 
and/or metastasis. These molecules, often expressed at low 
levels or absent on normal cells, usually affect adherence 
or migration of cancer cells, but they can also serve as the 
cell-entry receptors for OVs. For instance, cancer-specific 





58 are utilized by the oncolytic MV Edmonston 
strain, SV, and EV1, respectively. Additionally, some OVs can 
be genetically modified to retarget recombinant viruses to 









α-folate receptor (FRα), or epidermal growth factor receptor 
(EGFR).59–62 All these cancer-specific surface proteins, for 
example, can be found on most ovarian cancer cells.
Dysregulation of the tumor cell cycle
Mutations in tumor suppressor genes, such as p53 and Rb, 
may lead to dysregulation of cell cycle and suppression of 
apoptosis, creating a cellular environment favoring continued 
Table 1 Oncolytic viruses in preclinical studies on ovarian cancer therapy
Oncolytic virus Genome and structure Genetic modification Tumor selectivity Refs
Adenovirus  
(serotype 5)
36-kb dsDNA  
nonenveloped
E1B 55-kD deletion Aberrant p53 pathway and  
aberrant mRNA transport
90, 91
E1A CR2 deletion Aberrant Rb pathway 92, 93
Tropism modification RGD motif insertion targeting  
TS integrins
59
Ad5/3 chimeric capsid targeting  
TS desmoglein-2
103, 104
TSP-driven E1A expression 68, 105–107
Herpes simplex  
virus 1 and 2
∼150-kb dsDNA  
enveloped
γ 34.5 gene deletion Aberrant PKR signaling or  
Pi3K pathway
120, 121
ICP10 deletion Activated Ras-signaling pathway 127
Deletion of viral RR Upregulation of cellular RR 130




Upregulation of cellular TK




Natural attenuation Ras-signaling pathway,  
defective iFN pathway
136
Myxoma virus 160-kb dsDNA  
enveloped





24-kb dsRNA  
nonenveloped
None Activated Ras-signaling pathway 55




Targeting TS CD46 receptor





Mumps virus 15-kb ss(-) RNA  
enveloped
Attenuated vaccine Likely defective antiviral pathway 200
VSV 11-kb ss(-) RNA  
enveloped
None Defective iFN pathway 165
Maraba virus 11-kb ss(-) RNA  
enveloped
Attenuated strain Defective iFN pathway, and unknown,  
iFN- independent defects in cancer cells
174
Sindbis virus 12-kb ss(+) RNA  
enveloped
None Targeting TS LAMR, defective  
iFN pathway
57, 178
Echovirus type 1 7.5-kb ss(+) RNA  
nonenveloped
None Targeting TS integrin, defective  
iFN pathway
58, 201
Abbreviations: TSP, tumor-specific promoter; TS, tumor specific; TK, thymidine kinase; RR, ribonucleotide reductase; VEGF, vascular endothelial growth factor; 
iFN, interferon; PKR, protein kinase R; TNF, tumor necrosis factor; Pi3K, phosphatidylinositol 3-kinase; LAMR, laminin receptor.






proliferation of the cancer cells. Some OVs have been engi-
neered by deletion of essential viral genes involved in interac-
tion with cellular proliferation–regulatory proteins in normal 
cells, thus enabling selective replication of the OVs in tumor 
cells. For example, VV constructs that have been deleted in the 
viral thymidine kinase (TK) gene can only replicate efficiently 
in proliferating cancer cells that highly express cellular TK but 
less efficiently in normal noncycling cells with a low level of 
cellular TK.63 As another example, deletion mutation of the 
adenovirus E1A gene can preempt E1A interaction with Rb 
protein and thus restricts the replication of the mutant virus 
in cancer cells with missing or aberrant Rb.64
Tumor-specific promoter–controlled transcription
Restriction of OV replication in certain cancer cells can also 
be accomplished by insertion of a tumor cell–responsive 
tumor-specific promoter (TSP) that drives the expression 
of viral genes essential for virus replication. TSPs that have 
been tested in ovarian cancer cells include cyclooxygenase 2 
(COX2), vascular endothelial growth factor receptor (VEGF), 
mesothelin, midkine, survivin, the secretory leukoprotease 
inhibitor, and the C-X-C chemokine receptor type 4 
(CXCR4), and multidrug resistance gene 1 promoters.65–68
MicroRNA-regulated replication of OVs
The recent discovery that some specific microRNAs (miRNAs) 
are specifically dysregulated in cancer cells provides a new 
avenue for targeted replication of OVs in cancer cells. miRNAs 
are a class of small noncoding RNA molecules that regulate 
gene expression posttranscriptionally by binding to comple-
mentary sequence on mRNA targets and then blocking protein 
translation via the RNA-induced silencing complex. miRNAs 
whose expression is lost or greatly reduced in cancer cells have 
been used to control the expression of critical viral genes of 
several OVs, thereby confining OV replication to those cancer 
cells.69,70 To date, however, miRNA-regulated OVs have not 
yet been studied in ovarian cancer.
Ovarian cancer model systems
Established ovarian cancer cell lines have been generated 
and characterized throughout the ovarian cancer literature. 
Much is known regarding the genetic perturbations within 
many of these lines, particularly with the recent publication 
of data from genome-wide sequencing strategies.71,72 There 
are also well-defined data with respect to the tumorigenic 
capacity when implanted into immune-compromised mice 
with respect to take rate, tumor latency, route of injection, 
and combined administration of standard chemotherapeutics 
for ovarian cancer (ie, platinum agents and taxanes).73–75 
There are also concerted efforts by some groups to establish 
and use primary ovarian tumor cells directly from patients. 
For ovarian cancer, this not only entails growing cells from 
solid tumor biopsy specimens, but can be quite effectively 
performed by direct culturing of metastatic ovarian cancer 
cells from the malignant ascites fluid that accumulates in the 
majority of women with late-stage disease.76
The widely held belief is that epithelial ovarian cancer 
cells arise from lesions within the normal ovarian surface 
epithelial cells;77,78 however, more recently it has emerged 
that alternative origins likely exist as well. Historically, 
ovarian cancer cells are compared with either primary 
cultures of normal ovarian surface epithelial cells from 
oophorectomy specimens or – what has been more widely 
done – immortalized counterparts of these cells are used. 
Ovarian surface epithelial (OSE) cells immortalized with 
simian virus 40 (SV40) T antigen originally generated by 
Auersperg’s group have been commonly used,79,80 and since 
then human telomerase reverse transcriptase has also been 
applied.81 These immortal cell lines derived show no tumori-
genic characteristics in culture and in mice, but retain normal 
epithelial cell properties.81,82 Additional molecular events, 
such as coexpression of E-cadherin, are required for SV40 T 
antigen–immortalized human OSE to acquire tumor-forming 
potential.83 To address the putative fallopian tube origin of 
high-grade serous ovarian cancer, efforts have been initiated 
to generate fallopian tube secretory epithelial cell lines.84
Mouse models typically entail human ovarian tumor 
cell line xenografts into immune-compromised mice. For 
example, ES2 cells and A2780 cell lines are quite aggres-
sive and yield robust tumor and ascites growth within a short 
period.75,85 SKOV3ip1 cells are also useful for successful 
intraperitoneal (IP) injection and tumorigenesis studies.86 For 
using mouse models that possess an intact immune system, 
there has been the development of transgenic mouse lines that 
yield bilateral ovarian tumors due to SV40 T antigen expres-
sion targeted to the mouse ovarian surface epithelium.87 This 
contrasts with human OSE cells immortalized with SV40 T 
antigen alone, which is nontumorigenic in mice.82 In addi-
tion, there is the utility of using the ID8 transformed mouse 
OSE cell line, which can establish tumors when injected into 
syngeneic C57Bl/6 female mice.88
OV candidates for ovarian cancer
Adenovirus
Members of the Adenoviridae family are DNA viruses that 
commonly cause mild and self-recovered upper respiratory 
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tract and digestive tract infection in healthy people. There 
are 57 Ad serotypes identified in humans,89 of which Ad 
serotype 5 (Ad5) is most extensively studied and has been 
genetically modified into various recombinant conditionally 
replicative adenoviruses (CRAds) for treatment of cancer. 
CRAds possess specifically engineered elements in the 
viral genome that confer selective viral replication in cancer 
cells but disfavor replication in normal somatic cells. The 
best-known oncolytic CRAd is E1B 55-kDa gene-deleted 
Ad5 mutant dl1520 (also known as Onyx-015, developed 
by Onyx Pharmaceuticals).90 E1B 55 kDa protein has been 
shown in vitro to bind and inactivate the cellular tumor sup-
pressor p53 protein, thereby blocking p53-induced apoptosis. 
Originally, it was believed that prevention of p53-mediated 
apoptosis by E1B 55 kDa protein allowed wild-type (WT) 
Ads to replicate and propagate in normal cells, and hence 
Onyx-015 would only replicate in p53-defective cancer cells. 
However, E1B 55 kDa protein was subsequently found also to 
be involved in late viral RNA nuclear export, and this mecha-
nism, rather than p53 inhibition, is more likely to determine 
the tumor selectivity of Onyx-015.91 The effect of Onyx-015 
treatment on ovarian cancer was tested in nude mice bearing 
xenografted human ovarian cancer cells.92 It was shown that 
Onyx-015 was able to enhance survival of animals bearing 
human ovarian OVCAR3 or A2780/CP70 tumors. This find-
ing promoted Onyx-015 entrance into human clinical trials 
for ovarian cancer in early 2000.
Two other CRAds, containing a similar but not identi-
cal 24-bp deletion in the Rb-binding conserved region 2 
of the E1A gene that abrogates the binding of E1A to pRb, 
and designated dl922–947 and Ad5-∆24, respectively, 
were developed to target tumor cells defective in the Rb 
pathway.64,93 Binding of E1A to Rb is required for Ad to 
drive S-phase entry and cell cycle progression for optimal 
viral replication.94 Aberrant Rb pathway and consequent 
abnormal G1-S checkpoint, which can complement E1A 
with mutated conserved region 2 and permit the replication 
of Ad5-∆24 and dl922–947 in such tumor cells, are found 
in over 90% of human cancers, including ovarian cancer.95 
In vitro studies have shown that compared with WT Ad5 
and Onyx-015, dl922–947 induced greater cytotoxicity in 
IGROV1 and OVCAR4 ovarian cancer cells and certain 
other types of cancer cells.64,96 In the IGROV1 xenograft 
mouse model, dl922–947 displayed potent antiovarian 
tumor activity, comparable with WT Ad5.96 It has also been 
shown that dl922–947 improved antitumor activities in 
other cancer xenograft models, compared with Onyx-015 
and WT Ad.64
In addition to the genetic manipulation of the E1A and 
E1B genes, other approaches have also been exploited to 
optimize the oncolytic activity of CRAds for ovarian cancer, 
including tropism modification, TSP-controlled viral replica-
tion, arming Ads with therapeutic genes, chemotherapy–Ad 
combination therapy, and novel viral delivery methods.97
Tropism modification
The Coxsackie adenovirus receptor (CAR) is the main 
cellular receptor for Ad5. However, CAR is expressed on 
most normal human epithelial tissues and is often expressed 
at lower levels on ovarian and other primary cancer cells.98,99 
The large variation of CAR expression on tumor cells, at 
least in part, contributes to the oncolytic inconsistence often 
observed between preclinical and clinical studies using Onyx-
015 virus, eg, its relative ineffectiveness in the early clinical 
trials for ovarian cancer. To circumvent this CAR-dependent 
cell entry in order to better target tumor cells specifically, 
the Ad5 capsid was genetically modified to incorporate an 








, which are 
highly expressed on certain cancer cells, including most 
ovarian cancers.100–102 The derivative vector, Ad5-∆24-
RGD, replicated and killed several different human ovarian 
cancer cell lines (Hey, OV-4, and SKOV3) as efficiently 
as Ad5-WT E1A-RGD, and also replicated efficiently in 
ovarian cancer primary cell spheroids.59 Moreover, treatment 
of CB17 severe combined immunodeficiency (SCID) mice 
bearing xenografted OVCAR3 tumors showed potent 
antiovarian cancer therapeutic effects. Another strategy 
used to overcome the inherent CAR deficiency on most 
ovarian cancer cells was to replace the Ad5 CAR-binding 
motif with that from Ad3. This enabled the chimeric vector 
Ad5/3 to enter cells through a CAR-independent, Ad3 
receptor–dependent pathway. The Ad3 receptor, recently 
identified as the desmoglein-2 protein,103 is expressed at 
high levels on most ovarian cancer cells.104 When compared 
with Ad5lucRGD, the replication-incompetent luciferase 
(luc)-expressing Ad5/3 (Ad5/3luc) was more efficient in 
transduction of cultured ovarian cancer cell lines SKOV3.
ip1, Hey, and OV-4 as well as in human primary ovarian 
cancer cells isolated directly from patients.61 Both Ad5/3luc 
and Ad5lucRGD were superior to WT Ad5luc in infectivity 
in vitro and in a CD1 nude mice model with subcutaneous 
(SC) Hey tumor xenografts following intratumoral injection 
of viruses. Other in vitro studies also confirmed that 
Ad5/3 modification achieved higher infectivities in ovarian 
cancer cells than the mutant RGD variant.68,105 In another 
study, ovarian cancer retargeting was achieved by coating 






Ads with receptor-binding antibody-conjugated polymer 
that was covalently linked to Ad capsid.62
TSP-controlled Ad viral replication
With CRAds, the tumor specificity was improved using TSPs 
to drive E1A expression, which allowed limited viral replica-
tion in normal cells but not in tumor cells, and reduced the 
host toxicity caused by CRAds. Several TSPs (as mentioned 
previously) have been tested in ovarian cancer cell lines and 
in human primary ovarian cancer cells isolated from patients. 
TSPs in combination with tropism modification (Ad5/3 or 
RGD) have shown to have greater oncolytic activity and 
significantly reduced liver toxicity in an in vitro and in vivo 
ovarian cancer xenograft model, compared with WT Ad5 or 
no-TSP control viruses.68,105–107
Armed CRAds
Candidate genes that have been engineered into CRAds 
potentially to augment oncolytic virotherapy include cell-
suicide genes, genes that modify tumor microenvironment 
for enhanced viral infectivity, and immunoregulatory genes. 
Onyx-015 armed with the HSV TK gene has been shown 
to suppress tumor growth in the presence or absence of the 
prodrug ganciclovir in the MDAH 2774 xenograft tumor 
model.108 Interestingly, ganciclovir appeared to inhibit Onyx-
015 and reduced its tumor suppression effects. Similar results 
were also seen using Ad5/3-∆24-TK virus.109 A CRAd was 
engineered to carry the CXCR-4 promoter and the tissue 
inhibitor of metalloproteinase 2 (TIMP2) gene that targets 
cellular metalloproteinases to inhibit tumor growth and 
dissemination. The resultant mutant virus, Ad5/3-CXCR4-
TIMP2, showed more efficient in vitro killing of ovarian 
cancer cells than the unarmed viruses.67 However, the in vivo 
antitumor activity of Ad5/3-CXCR4-TIMP2 remains to be 
investigated.
Chemotherapy–CRAd combination therapy
Accumulating evidence indicates that chemotherapeutic 
agents or radiotherapy can be combined with OVs such as 
the CRAds to significantly enhance therapeutic effects in 
the treatment of cancers compared with either treatment 
alone. For example, the combination of Ad5/3-∆24 with 
gemcitabine (a nucleoside analog), or epirubicin (a DNA-
 intercalating anthracycline drug) resulted in greater therapeu-
tic efficacy than either agent alone in ovarian cancer xenograft 
models.110 Combination of dl922–947 with paclitaxel or 
combination of the survivin promoter–containing vector 
CRAd.S-RGD with cisplatin also had significantly greater 
therapeutic benefits than single-agent treatments in ovarian 
cancer xenograft models.111,112 It was suggested that cispla-
tin and gemcitabine might act to increase viral replication, 
whereas paclitaxel and dl922–947 together induced aberrant 
mitotic slippage and multinucleation, leading to a more 
efficient apoptotic cell death.
Enhancement of viral delivery
Ads commonly cause subclinical human infections that 
usually induce protective neutralizing antibody responses in 
virus-infected people. For example, approximately 40%–69% 
of the adult population in the US are seropositive to Ad5.113 
Preexisting anti-Ad5 antibodies in humans may reduce clini-
cal efficacy of intratumorally injected Ad5-based vectors and 
represents a serious hindrance to the clinical application 
of systemically administered CRAds. Furthermore, direct 
injection of Ads may also cause higher systemic toxicity 
responses in patients, especially in the liver. In order to 
overcome these barriers, two strategies have been developed 
to enhance the therapeutic effects of Ad delivery on ovarian 
cancer. The first strategy is to coat the viral particles with 
liposome polymers, which would shield the antibody-binding 
sites on Ad capsids from preexisting neutralizing antibodies 
and also reduce antiviral humoral responses as well as liver 
uptake of the virus.114,115 Using this method, liposome-coated 
Ad5 armed with the antiangiogenic agent endostatin had 
increased in vitro transfection capacity in SKOV3 cell lines 
and also had enhanced antitumor effects in a SC SKOV3 
xenograft nude mouse model when the virus was administered 
through intravenous (IV) administration.116 Another strategy 
for targeted delivery enhancement is to load mesenchymal 
stem cells (MSCs) with Ads before viral administration. One 
advantage of MSCs over other potential virus-carrier cells 
is that MSCs can be readily generated from patients’ own 
adipose tissues and grown to a large quantity. MSCs have 
been shown to display preferable homing to ovarian tumors 
after IP injection in an ovarian cancer xenograft model.117 
It has also been demonstrated that Ad5/3 and Ad-RGD 
viruses could efficiently infect MSCs without induction 
of severe cytopathic effects.117 When tested for antiovarian 
cancer effects, MSCs loaded with Ad5/3 or Ad5-D24-RGD 
induced cell killing of ovarian cancer cells and significantly 
suppressed tumor growth and prolonged survival in the 
SKOV3 xenograft animal model.117,118 MSCs loaded with 
Ad5-D24-RGD were as effective a strategy as administration 
of the virus alone, but showed a dramatic decrease in systemic 
spread of the virus, suggesting much less virus-associated 
systemic toxicity in the treated mice.118
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Herpes simplex viruses
Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are mem-
bers of Herpesviridae, a virus family of large, enveloped, 
dsDNA viruses. Both viruses infect most humans, with about 
two-thirds of the adult population being seropositive for one 
or both of the viruses.
HSV-1 and HSV-2 have been developed as oncolytic 
agents by genetically modifying the viral genomes for more 
targeted replication in cancer cells. For example, in the HSV-1 
vector Baco-1, both copies of the viral γ34.5 genes encoding 
the ICP34.5 neurovirulence factor were deleted and a green 
fluorescent protein (GFP)-expression cassette was inserted 
elsewhere in the viral genome.119 ICP34.5 recruits cellular 
protein phosphatase-1α to dephosphorylate eIF2α, thereby 
counteracting the PKR signaling pathway.120 ICP34.5 also 
interferes with the phosphatidylinositol 3-kinase (PI3K) 
pathway.121 HSV-1716, an attenuated HSV-1 mutant with 
deletion of a 759-bp DNA fragment and showing ICP34.5 
deficient phenotype,122 was among the first OVs to treat 
ovarian cancer in animal models.123 HSV-1716 treatment 
significantly suppressed tumor burden in SCID mice bear-
ing human ovarian SKOV3 or A2780 tumors. Moreover, 
treatments with PA-1 teratocarcinoma cells carrying HSV-
1716 showed greater antitumor activity compared with virus 
treatment alone. However, HSV-1716 and other similar 
HSV-1 vectors with deletion in γ34.5 genes, although show-
ing tumor cell–killing abilities in preclinical studies, did 
not significantly affect tumor growth or improve prognosis 
in early clinical trials.124,125 To improve the potency of this 
first generation of the HSV-1 vector Baco-1, a hyperfuso-
genic glycoprotein gene of the gibbon ape leukemia virus 
(GALV.fus) was inserted by replacing the GFP-expression 
cassette.126 When the resultant engineered HSV-1, called 
Synco-2D, was compared with Baco-1 for its induced 
cytopathic effects on human ovarian cancer cells Hey-8 
and SKOV3 in vitro, Synco-2D produced more pronounced 
syncytial formation and killed infected ovarian cancer cells 
more rapidly. In nude mice bearing IP Hey-8 xenografts, IP 
injection of Synco-2D resulted in 100% of mice surviving 
to the end of the experiment and 75% of the treated mice 
being tumor-free, whereas only 60% of Baco-1–treated mice 
survived and all bore large tumors. All mice died in the con-
trol mock-treated cohort. Another engineered HSV-2 based 
GALV.fus-expressing oncolytic vector was tested in ovarian 
cancer. This vector, named FusOn-H2, contains an additional 
modification, ie, deletion of the viral ICP10 gene. ICP10 
encodes in its N-terminus a serine/threonine protein kinase 
domain that can activate the Ras signaling pathway and is 
required for efficient HSV-2 replication in normal cells.127 It 
was also shown that FusOn-H2 had a greater ability to eradi-
cate tumors in nude mice bearing IP disseminated SKOV3 
xenografts (more than 80%) than Baco-1 (12%). These data 
suggest that oncolytic HSV armed with GALV.fus may provide 
a novel therapy for ovarian cancer.
In another recent study, it has been shown that carrier 
cell–based delivery of oncolytic HSV-1 mutants can improve 
antitumor effects against ovarian cancer through the ampli-
fication of the viral load and avoidance of neutralizing 
antibodies. This was tested using attenuated HSV-1 mutant, 
Hh101, and using human peritoneal mesothelial cells as cell 
carriers in a nude mice model xenografted with SKOV3 tumor 
cells.128 In this model, Hh101 carried in mesothelial cells 
significantly improved the antitumor activities of the virus 
compared with the Hh101 virus–alone treatment. Hh101 is 
an HSV-1 mutant isolated from Vero cells coinfected with 
HF10, a naturally attenuated virus derived from the HSV-1 
HF strain,129 and hrR3, an early generation of HSV-1 vector 
deleted in U
L
39 gene encoding ribonucleotide reductase.130 
Hh101 has also been shown to effectively treat disseminated 
peritoneal colon carcinoma in a BALB/c mouse model.131
The role of host immune responses in HSV-mediated 
oncolytic virotherapy has been studied. Using HSV-1716 
and a syngeneic mouse model of murine ID8 ovarian cancer 
cells expressing VEGF, it was demonstrated that IP injection 
of HSV-1716 led to the suppression of tumor growth and 
enhancement of mouse survival.132 Virus treatment–induced 
infiltration of monocytes and dendritic cells to the tumor and 
also upregulated the level of IFN-inducible chemokines, 
including monokine-induced gamma IFN protein (called 
MIG, now known as CXCL9) and IFN gamma-induced pro-
tein 10 (IP-10).132 Activated natural killer (NK) cells or CD8+ 
T cells were also recruited to the tumor microenvironment, 
likely mediated by MIG and IP-10. In addition, tumor cells 
infected with HSV-1716 expressed viral glycoproteins on 
the cell surface and were highly phagocytosed by dendritic 
cells, leading to induction of vaccination effects. These data 
indicated that HSV-1716, and possibly other oncolytic HSV 
vectors as well, exert their most oncolytic activities when 
they elicit both antitumor immune responses as well as direct 
killing of tumor cells.
Vaccinia virus
VV is a large enveloped dsDNA virus belonging to the 
Poxviridae family. Some strains of VV used as attenuated 
live-virus vaccines against smallpox have been studied as 
replicating OV agents. These VV vaccines can be further 






attenuated to increase cancer selectivity by deletion of 
specific viral genes. Some of these genes include the viral 
TK and VV growth factor (VGF) genes.133,134 TK is critical 
for VV DNA synthesis, particularly to infect normal cells, 
where nucleotide pools are typically low. Deletion of the 
VGF gene renders the virus defective in its ability to stimu-
late cell proliferation of noncycling cells to prime them for 
VV infection.
The deleted TK gene is often replaced with ectopic 
reporter genes (eg, luc, Escherichia coli beta galactosidase 
gene lacZ, or GFP) or therapeutic genes (eg, granulocyte-
 macrophage colony-stimulating factor [GM-CSF]) to 
facilitate monitoring virus spread or to improve antitumor 
activities, respectively. For example, rVV4 is a hyper-attenuated 
recombinant derivative of the vaccine strain Lister of VV, 
containing both lacZ and luc inserted into the TK gene.135 
rVV4 has shown oncolytic efficacy in both human ES-2 
ovarian cancer cells in nude mice (significant tumor reduc-
tion with no ascites accumulation and 100% of mice survived 
to 70 days posttreatment; controls survived to 28 days) and 
Defb29 Vegf mouse ovarian tumor cells in C57Bl/6 mice 
(infection led to significant tumor necrosis and cell death, 
and survival up to 63 days after treatment; controls survived 
to 42 days). Another TK-deletion VV construct, JX-594, was 
engineered from the Wyeth vaccine strain of VV. JX-594 also 
has insertions of lacZ or luc, and expresses human GM-CSF. 
This virus can infect and kill human ovarian cancer cells 
in vitro and specifically infect autochthonous ovarian tumors 
when injected IP into transgenic FVB/N mice expressing 
SV40 T antigen driven by the Müllerian inhibitory substance 
type II receptor promoter.87,136 In addition to singly TK-
deleted VV, the TK and VGF double-deleted virus (vvDD) 
has also been tested in ovarian cancer. vvDD has potent 
oncolytic activities in mouse MOSEC cells, human ovarian 
cancer cell line A2780, and human primary ovarian tumor 
cells in vitro, and in nude mice bearing IP A2780 tumors.137 
When vvDD was armed with a yeast cytosine deaminase 
(CD) gene that can been paired with prodrug 5-fluorouracil 
for enhanced chemotherapy, the resultant vvDD-CD virus in 
combination with 5-fluorouracil displayed higher antitumor 
activity than vvDD-CD alone in the syngeneic IP MOSEC 
C57Bl/6 mouse model.137
VV combined with other therapeutic agents can also aug-
ment its oncolytic activities. Recombinant VV as an oncolytic 
monotherapy requires repeated treatments; however, induced 
neutralizing antibodies can potentially limit the booster effect 
of subsequent inoculations, particularly in those who have 
been previously vaccinated against smallpox. To circumvent 
this, cotreatment with COX2 inhibitors reduces the genera-
tion of neutralizing antibodies due to VV administration.138 
Mouse ovarian tumor MOSEC cells expressing luciferase 
injected into C57Bl/6 mice and treated with COX2 inhibi-
tor exhibited higher viral titers when rechallenged with 
rVV4 with significantly fewer antibodies than control mice 
untreated with COX2 inhibitor. The doubly treated mice also 
showed reduced tumor growth and longer survival compared 
with rVV4 or COX2 treatments alone. Alternatively, 
limitation of repeated administration can be circumvented 
by using different OVs. It has been shown that VV injection 
followed by injection of another OV, the alphavirus Semliki 
Forest, or vice versa, induced longer survival than either virus 
alone in C57Bl/6 mice with MOSEC IP engraftments.139 
Moreover, sequential treatment of MOSEC tumor-bearing 
C57Bl/6 mice with VV expressing ovalbumin and Semliki 
Forest virus expressing ovalbumin induced higher CD8+ 
T-cell immune responses and longer animal survival than 
treatment with single virus alone. These results suggest that 
the efficacy of oncolytic virotherapy could be improved by 
employing different OVs and combining tumor antigen–
specific immunotherapy.
Myxoma virus
MYXV is a poxvirus with a very restrictive rabbit-specific 
tropism in nature but which is completely apathogenic and 
safe to all non-lagomorphs tested, including mice, rats, and 
humans. In vitro, MYXV has been shown to infect and kill a 
wide variety of human cancer cells.140 The tumor selectivity 
of MYXV depends in part on dysregulated intracellular 
signaling pathways in the cancer cells, specifically the PI3K 
pathway and the activation of Akt (p-AKT).141,142 An ankyrin 
repeat–containing host-range protein of MYXV termed 
M-T5 can directly bind to and induce the kinase activity of 
Akt, which allows more robust viral replication in cancer 
cells.135 Recently, MYXV has been shown to possess potent 
oncolytic activity against human epithelial ovarian cancers 
from both cell lines and ascites-derived primary patient cells. 
OVCAR3, OVCA429, SKOV3 human ovarian cancer cell 
lines, and ∼55% of patient samples tested demonstrated 
susceptibility to MYXV killing in monolayer.143 In an 
in vitro model of ovarian cancer metastasis, cells cultured 
in ultralow attachment plates to form multicellular spheroids 
(the hypothesized vehicles for ovarian cancer metastasis) 
were also infected by MYXV. Spheroids formed from both 
cell lines and ascites-derived patient samples that were 
infected with MYXV were killed and showed decreased 
reattachment upon reintroduction to adherent culture, 
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thus demonstrating the potential antimetastatic properties 
of this virus. The oncolytic properties of MYXV correlated 
with the level of p-Akt found in specific cell culture condi-
tions, ie, an increase in p-Akt levels in monolayer showed 
greater killing, whereas decreased p-Akt levels in spheroids 
had little killing until reattachment in adherent culture. Thus 
it is predicted that MYXV will have particular utility for 
targeting metastatic spread of this cancer, but this remains 
to be tested in vivo.
Measles virus
MV is a member of the Paramyxoviridae family and is an 
enveloped, single-stranded, negative-sense RNA virus that 
causes rash, fever, runny nose, cough, muscle pain, and red 
eyes in an infected person. A live attenuated MV vaccine 
strain called Edmonston has been developed as an effective 
oncolytic virus for treatment of ovarian cancer in preclinical 
studies.144 Upon viral infection, the hemagglutinin envelope 
glycoprotein of the oncolytic MV binds to the cellular 
receptor CD46, a cofactor for inactivation of complement, 
and subsequently the fusion glycoprotein induces fusion of 
viral-cell membranes.56 Expression of hemagglutinin and 
fusion proteins on the surface of virus-infected cells results 
in intercellular fusion of multiple neighboring uninfected 
cells with the infected cell, a characteristic MV-induced 
cytopathic effect (CPE) called syncytia. Extensive formation 
of syncytia causes apoptotic cell death of not only infected 
cells but also uninfected neighboring cells, a bystander killing 
that may augment the oncolytic activity of MV. CPE effects, 
however, are only induced when infection takes place in 
cells with more than a required minimum density of CD46 
receptor expression.145 Normal cells usually express only a 
low level of CD46. Therefore, infection of normal cells does 
not cause CPE and cell death. The safety of oncolytic MV 
has been demonstrated in measles replication–permissive 
animal models, including a CD46 transgenic mouse model 
and macaque models.146,147 The CD46 receptor is highly 
expressed in ovarian cancer cells, rending ovarian cancer an 
ideal target for MV virotherapy.148–150 A modified oncolytic 
MV expressing the soluble extracellular domain of human 
carcinoembryonic antigen (CEA) was created to monitor 
viral replication noninvasively in vivo.151 MV-CEA was able 
to kill a panel of ovarian cancer cells in vitro. Furthermore, 
intratumoral injection of MV-CEA led to 80% complete 
tumor regression in SC SKOV3.ip1–engrafted athymic nude 
mice, and IP administration of the virus greatly enhanced 
the survival of IP SKOV3.ip1 xenograft mice.144 In addition, 
it was also confirmed that CEA expression could be used as 
a marker for the presence of MV-CEA replication post–viral 
administration. These results provided the basis for the sub-
sequent phase I clinical trial with MV-CEA in patients with 
recurrent ovarian cancer. Interestingly, in a following study 
testing multiple dosages in an IP xenograft animal model, 
Peng et al reported that IP treatments with either six doses 
of 103 or single or six doses of 104, 105, or 107 median tissue 
culture infective dose (TCID
50
) MV-CEA resulted in equiva-
lent anti-tumor effects.152 These results suggested that in vivo 
tumor growth and MV infection/replication could reach an 
equilibrium state regardless of the initial infection doses. 
In addition to CEA, the thyroidal sodium iodide symporter 
(NIS) was also inserted into the MV genome for monitoring 
viral propagation, which can be mapped by serial radioiodine 
imaging. Results using MV-NIS suggested that MV-CEA 
and MV-NIS had comparable tumor suppression activity 
in vivo.153 A more attenuated Edmonston strain–derived MV 
vaccine, called MV-Moraton, and another live virus vaccine 
from the Paramyxoviridae family, Jeryl Lynn mumps, have 
also been investigated for their possible oncolytic activity. The 
results showed that both viruses have potent antiovarian tumor 
activities comparable with MV-CEA in xenograft models.154 
MV-Moraton and Jeryl Lynn mumps are commercially avail-
able vaccines and have been used in more than 300 million 
people. The proven safety profile in humans and the capacity 
for mass production make these two viruses appealing OV 
candidates for cancer therapy in general.
A tropism-modified MV has also been generated and 
studied for its potential application in ovarian cancer. To 
minimize potential CD46-associated immune suppression 
and virus sequestration by non–target tissues after MV 
administration, the hemagglutinin protein of MV was geneti-
cally modified to incorporate a single-chain antibody (scFv) 
specific for FRα while eliminating its CD46 binding.60 FRα 
has been found to be overexpressed in various cancers 
including 90% of ovarian cancer, whereas in normal tissue, 
FRα is only expressed at the apical surface of polarized epi-
thelial cells.155,156 The recombinant virus MV-FRα reduced 
its background viral infection levels on normal cells and 
targeted only FRα-expressing cancer cells. The virus retained 
complete antiovarian cancer activity of the parental MV, as 
demonstrated in SC and IP SKOV3.ip1 xenograft models.
MSCs have also been tested as the virus-carrying vehicle 
in an attempt to protect MV from preexisting neutralizing 
antibody and to improve targeted delivery of the virus to 
ovarian tumors. It was shown that MV-infected MSCs could 
efficiently reach and infiltrate into IP SKOV3.ip1 tumors 
for virus delivery in measles-naive athymic mice and also 






in mice passively immunized with human measles immune 
serum.157 This resulted in effective enhancement of animal 
survival in the tumor-bearing cohorts. In contrast, no such 
effect was displayed when passively immunized mice were 
treated with naked virus or uninfected MSCs.
Reovirus
Reoviruses are nonenveloped viruses with a genome consist-
ing of 10–12 dsRNA segments. Reoviruses were initially 
named respiratory enteric orphan viruses because they were 
commonly isolated from human respiratory and gastroin-
testinal tracts but are not apparently associated with human 
diseases. Reovirus serotype 3 Dearing strain has been devel-
oped as an OV under the trade name Reolysin (Oncolytics 
Biotech).158 It is very difficult to genetically modify reovirus 
using classic reverse-genetic approaches because of the 
segmented dsRNA viral genome. Nevertheless, the WT, 
unaltered Reolysin, has potent intrinsic oncolysis activities. 
Reovirus specifically targets and kills cancer cells with an 
activated Ras signaling pathway that leads to the inhibition 
of PKR activation.55 In normal cells, it is believed that PKR 
is activated by reovirus genomic dsRNA segments and viral 
dsRNA transcripts. As a result, reovirus cannot express 
sufficient viral proteins for continued replication in normal 
cells, in contrast to the productive virus infection in tumor 
cells that possess deficient PKR activation. It has also been 
suggested that the oncolytic activity of reovirus is mediated 
by TNF-related apoptosis-inducing ligand (TRAIL)-induced, 
caspase 3/8-dependent apoptosis.159,160
Mutations in the Ras signaling pathway are often found 
in patients with ovarian cancer,161 indicating that ovarian 
cancer is a potential therapeutic target for reovirus. In an 
early in vitro study, Reolysin efficiently infected and killed 
four human ovarian cancer cell lines (MDAH2774, PA-1, 
SKOV3, and SW626), primary ovarian cancer cells from 
patient samples, but not a normal ovarian fibroblast cell 
line (NOV-31).162 It was further demonstrated that intra-
tumoral injection of Reolysin induced regression of SC 
SKOV3 tumors in nude mice, and IP administration of the 
virus inhibited ascites formation and prolonged survival of 
treated mice in an IP MDAH2774 xenograft model. This 
study also showed that Reolysin specifically and effectively 
infected distal colon tumors in the SC flank, but not normal 
tissue surrounding the tumor, following IV delivery of the 
virus. Reolysin infection of ovarian cancer cells could also 
sensitize the cells to recombinant TRAIL, an anticancer agent 
currently being tested in clinical trials,163 possibly via down-
regulation of cellular FLICE/caspase-8 inhibitory protein.159 
This suggests that combination of reovirus and TRAIL could 
be more effective than either regimen alone in the treatment 
of ovarian cancer.
Vesicular stomatitis virus
VSV is an enveloped, negative-stranded RNA virus of the 
Rhabdoviridae family. Viruses in this family are attractive 
OV candidates, because with the exception of rabies, they 
are rarely associated with diseases in humans. Moreover, 
few people have preexisting immunity in most populations 
worldwide.
VSV binds to and enters mammalian cells through an 
unidentified receptor that is ubiquitously expressed in nor-
mal cells and malignant cells.164 Infection of normal cells 
strongly induces interferon-mediated antiviral responses, and 
thus virus replication is blocked. By contrast, cancer cells 
frequently have defective interferon signaling pathways, 
allowing for unchecked viral replication. A dysregulated 
PKR pathway is the one of the key factors for determination 
of the tumor selectivity of VSV.165 Viral protein expression 
and replication likely kill virus-infected cancer cells by the 
induction of apoptotic cell death during metaphase, which 
is triggered by inhibition of mitotic progression by VSV 
infection.166
It has been shown that VSV is a potent oncolytic in a wide 
variety of cancer models,167 including ovarian cancer.168–170 
In vitro, a VSV vector–expressing GFP (VSV-GFP) was 
able to efficiently infect and kill various ovarian cancer cell 
lines and ovarian surface epithelial cells transformed with 
SV40 T antigen within 3 days.169 By contrast, infection of 
normal primary human ovarian epithelial cells was detected 
in only about 5% of the cells, and no cytotoxicity effects 
were observed 3 weeks postinfection. The antiovarian cancer 
efficacy of VSV-GFP has also been tested using an immu-
nocompetent white spotting variant (Wv) mouse model.169 
Wv mice have a naturally occurring point mutation in the c-kit 
gene, causing defects in the development of germ cells.171,172 
Nearly 100% of homozygous Wv mice develop ovarian 
epithelial tumors, defined as tubular adenomas, as early as 
3 months of age.173 This type of epithelial ovarian tumor is 
benign, but can gain increasing neoplastic changes in older 
mice. Treatment of tumor-bearing Wv mice with VSV-GFP 
via intrabursal, IP, or IV administration was shown to greatly 
reduce the tumor burden without inducing detectable toxicity 
effects.169 Examination of GFP signals in treated Wv mice 
10 days after virus injection indicated that VSV selectively 
targeted the in situ ovarian tumor, while no GFP expression 
was detected in any other organs and tissues. In another study, 
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using an IP human ES-2 ovarian cancer xenograft model, 
Stojdl and colleagues showed that a VSV virus (AV2) with 
mutated matrix protein and enhanced ability to induce IFN 
responses in normal cells enhanced survival of virus-treated 
animals.170 AV2 has slightly decreased oncolytic activity 
in ovarian cancer cells in vitro compared with WT VSV. 
However, AV2 is highly attenuated in BALB/C mice, sug-
gesting that it may be safer for clinical applications.
Maraba mirus
Like VSV, MRB is a member of the Rhabdoviridae family. 
In a comparison of oncolytic activity across this family, 
MRB was shown to have the highest degree of killing in 
an array of cancer cell lines, including those from ovarian 
sources.174 To improve replication and decrease toxicity, 
two point mutations were made in MRB (MRB MG1) that 
were homologous to two point mutations made in VSV that 
improved replication of VSV. In an ES-2 xenograft model of 
ovarian cancer, low doses of MRB MG1 showed significant 
decreases in tumor burden. Moreover, there was a dose-
dependent tumor response to MRB MG1, and it demonstrated 
better efficacy at all doses when compared directly with a 
VSV construct.
Sindbis virus
SINV is a member of the Togaviridae family that is an envel-
oped, positive-stranded RNA virus that infects natural host 
birds and transfers vector mosquitoes. Infection in humans 
can occur when a person is bitten by infected mosquitoes, but 
generally causes very mild symptoms. SINV as a blood-borne 
pathogen is stable in the bloodstream, which may enable 
more efficient systemic delivery of the virus. SINV has an 
inherent tropism for tumor cells. The SINV receptor LAMR 
is overexpressed in ovarian cancer cells175 and many other 
types of tumor cells,176 and is important to mediate cancer cell 
migration and metastasis.177 Like VSV, SINV is highly sensi-
tive to IFN, and thus can only replicate in cancer cells with 
acquired genetic defects in the IFN-signaling pathway, but 
not in normal cells with intact innate immune responses.178 
Productive infection, at least with VSV, likely causes cancer 
cell death by inducing apoptosis.179
SINV virotherapy of ovarian cancer was first tested 
using an SCID mouse model bearing IP human ES-2 ovarian 
cancer xenografts and a syngeneic C57Bl/6 mouse model 
with IP engraftment of murine MOSEC ovarian cancer 
cells.180 It was found that IP injection of SINV significantly 
suppressed tumor growth in both models. Survival analy-
sis in the syngeneic model also confirmed the antitumor 
activities of SINV. An attenuated laboratory SINV strain, 
AR339, also suppresses tumor growth in a human OMC-3 
ovarian cancer xenograft model.181 By using in vivo imaging 
of SINV expressing firefly luciferase and ES-2 cells express-
ing Renilla luciferase, combined with histologic analysis, 
virus infection colocalized with the tumor tissue in vivo, 
suggesting that virus infection is tumor-specific. In addition 
to the oncolysis of cancer cells, SINV also was also shown 
to induce a potent bystander antitumor immunity.178 This 
antitumor immunity is likely mediated by activation of NK 
cells.182 Correspondingly, SINV oncolytic vectors express-
ing interleukin (IL)-12 or IL-15, two cytokines known to 
elicit antitumor activity by activation of natural killer cells, 
exhibit more potent antitumor activity than SINV express-
ing lacZ.180,182
Echovirus type 1
EV1 is a nonenveloped, single-stranded, icosahedral RNA 
virus of the Picornaviridae family. EV1 is isolated from the 
gastrointestinal tract and causes no or mild upper respiratory 




 is highly expressed 
on ovarian cancer cells, but is only present on normal surface 
epithelium at a low level.183 In vitro, EV1 induces strong 
cytopathic effects in various ovarian cancer cell lines, but 
not in immortalized human OSE cells or human peripheral 
blood mononuclear cells.184 EV1 can also infect and kill 
multicellular spheroids of ovarian cancer cells DOV13. 
When tested in SCID mice bearing OVHS-1 xenografts, both 
intratumoral and IP injections of EV1 were shown to suppress 
tumor burden significantly. In an SC xenograft model, none 
of EV1-treated mice reached experiment end points (tumors 
exceeding 20% of body weight) after the experiment was 
ended 14 weeks post–virus administration, whereas all mice 
without virus treatment reached end points within 3 weeks. 
These results suggest EV1 is also a potential oncolytic virus 
candidate for the treatment of ovarian cancer.
Clinical applications
Clinical studies using OVs to treat ovarian cancer is still in its 
infancy. As of April 2012, results from three phase I clinical 
trials in ovarian cancer have been published, involving Onyx-
015,185 Ad5-∆24-RGD,186 and measles virus MV-CEA.149 
A phase I clinical trial testing JX-594 in patients with differ-
ent types of cancers including ovarian cancer has also been 
published.187 Ad5-D24-GMCSF and Ad5/3-D24-GMCSF 
have also been evaluated under compassionate use regulated 
by the Finnish Medicines Agency FIMEA.188,189 In addition, 
there are two ongoing trials with Reolysin in ovarian cancer 






Table 2 Summaries of clinical trials of oncolytic virotherapy in patients with ovarian cancer






MV MV-CEA i 21 14 SD 5 PR Mild 149
Ads Onyx-15 i 16 No clear response No response 1 DLT, 15 mild 185
Ad5-∆24-RGD i 21 15 SD 7 MR Mild 186
Ad5-∆24-GMCSF CU** 4* (20) 1 CR, 1 SD, 1 MR 1 CR, 1 PR, 1 SD Mild 188
Ad5/3-∆24-GMCSF CU** 4* (21) 1 SD 1 MR Mild 189
VV JX-594 i 2* (23) 2 SD Mild 187
GL-ONC1 i/ii Recruiting 193
Reovirus Reolysin i Recruiting 194
Reolysin (with paclitaxel) ii Recruiting 195
Notes: *Number of patients with ovarian cancer, out of the total number of patients with various types of cancer, indicated in the parentheses, in the corresponding clinical 
trial; **studies under compassionate use regulated by the Finnish Medicines Agency FiMEA. With regard to CA-125 tumor markers, MR, PR, SD, and CR indicate a less than 
29% decrease, a more than 30% decrease, stabilization, and a normal level in tumor marker, respectively.
Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease; CU, compassionate use. 
and one ongoing trial with attenuated VV GL-ONC1 for 
all peritoneal metastatic cancers including ovarian cancer, 
according to the NIH website ClinicalTrials.gov. Although 
early phase trials mainly address the safety, maximum toler-
ated dose, and toxicity spectrum of OVs, antitumor efficacy, 
viral replication, and antibody responses are also analyzed. 
Clinical efficacies are assessed by Response Evaluation 
Criteria in Solid Tumor (RECIST) criteria and cancer antigen 
(CA)-125 response. CA-125, also known as mucin 16, is a 
protein biomarker for recurrence of ovarian cancer.190 In all 
studies, eligible ovarian cancer patients have persistent or 
recurrent ovarian cancer, fallopian tube cancer, or primary 
peritoneal cancer after prior treatment with chemotherapy. 
The enrollees are older than 18 years and have adequate 
organ function. Participating patients, except for those in 
the JX-594 trial, receive administration of OVs through an 
IP catheter. All these clinical studies have shown that OVs 
were well tolerated, and no maximum tolerated doses were 
reached in any of the trials. Encouraging antitumor responses 
were observed in all but the Onyx-015 trial. Summaries of 
the clinical studies are provided in Table 2.
Onyx-015
The first human OV trial for ovarian cancer was conducted 
with adenovirus Onyx-015 in 16 patients.185 Four dose levels 
of virus (1 × 109, 1 × 1010, 3 × 1010, and 1 × 1011 plaque-
forming units [pfu]) were tested in this trial. For a particular 
dose level, Onyx-015 was administered to patients daily for 
5 days (one cycle) every 4 weeks. These patients received a 
total of 35 cycle treatments, with a mean of two cycles per 
patient. Most patients experienced common toxicity criteria 
grade 1 or 2 flu-like syndrome and abdomen pain after virus 
infusion. Only one patient who received 1 × 1010 pfu exhibited 
common toxicity criteria grade 3 abdominal pain and grade 3 
diarrhea, and the patient’s toxicity profile was considered 
dose-limiting. No grade 4 toxicity was noted in any patient. 
This toxicity study indicates that Onyx-015 administration 
is safe at the highest dosage tested. Viral DNA was detected 
10 days after the last dose of virus in five of eight patients 
who were subjected to polymerase chain reaction (PCR) 
testing of peritoneal specimens. No viral DNA was detected 
in the blood samples in these patients. Interestingly, viral 
DNA was still detected in one patient 354 days after final 
virus treatment. These data, however, were not sufficient 
to prove the presence of viral replication since an increase 
in viral genome copy number was not shown. Antiadenovirus 
antibody responses were evident in 12 of 13 patients that 
were examined. Unfortunately, there was no clear evidence 
of antitumor activities induced by Onyx-15 in this trial. Four 
of the 16 patients showed brief stable disease after more 
than two cycles of Onyx-015, but soon developed progres-
sive disease. Eventually, all patients stopped virotherapy 
because of development of progressive disease, except one 
who was removed from the trial due to Onyx-015 dose-
limiting toxicity.
Ad5-∆24-RGD
The tropism-modif ied Ad5-∆24-RGD virus has been 
engineered to improve cancer-targeting and the oncolytic 
activity of early adenovirus vectors, such as Onyx-015, 
in preclinical studies. Consistently, a phase I clinical trial 
with Ad5-∆24-RGD has yielded promising antiovarian 
cancer responses.186 In this clinical trial, vector dosages of 
Ad5-∆24-RGD ranging from 1 × 109 viral particles per day 
(vp/d) to 1 × 1012 vp/d, with increase of 1/2 log vp/d in each 
successive cohort tested in 21 patients, of whom 18 patients 
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had recurrent ovarian cancer. Virus was delivered daily for 
3 consecutive days, and the patients were followed up on days 
0–3, 7, 14, and 28 to evaluate toxicity, virus replication, and 
antitumor efficacy. As for the clinical study with Onyx-015, 
Ad5-∆24-RGD treatment did not cause significant toxicity. 
Although no partial or complete responses were observed, 
15 patients (71%) were shown to have stable disease. 
In addition, seven patients (33%) had deceased CA-125 
levels, and four of them had .20% reduction. RGD-specific 
viral DNA was detected in ascites in 16 of 21 patients by 
quantitative real-time (qRT) PCR after virus treatment. 
More importantly, increased viral DNA copy number was 
detected at various time points after day 3 of virus treatment 
in seven patients, suggesting viral replication in the cancer 
cells. Immunohistochemistry analysis of ascites from selected 
patients confirmed the infection of ovarian cancer cells by the 
virus. Dose-dependent antiadenovirus neutralizing antibody 
response was generally detected in ascites and serum in all 
patients. Unlike Onyx-015, Ad5-∆24-RGD DNA was also 
found in serum (ten patients), saliva (ten patients), and urine 
(nine patients), probably due to high replication activity of 
Ad5-∆24-RGD in the IP cavity, leading to the dissemination 
of the virus.
MV-CEA
MV-CEA has been tested in 21 patients with recurrent ovar-
ian cancer in a phase I trial study.149 Patients were treated 
with seven escalating doses of MV-CEA (103–109 TCID
50
 
at 1-log increments) every 4 weeks for up to six cycles. No 
dose-limiting toxicity was observed with MV-CEA. Most 
toxicities were grade 1 or 2 fever, fatigue, and abdominal 
pain. Fourteen of the 21 patients (67%) had stable disease 
with median duration of 92.5 days. Nine of the 14 patients 
with stable disease (64%) were in the three highest dose lev-
els, indicating dose-dependent outcomes. CA-125 levels were 
demonstrated to decrease .30% in five patients. Median 
overall survival of the patients in this trial was 12.15 months, 
while in similar patient populations the median survival is 
expected to be 6 months. Viral DNA was detected in the 
blood in four patients by qRT-PCR, but no virus shedding 
was detected in saliva and urine in any patient. CEA levels 
were elevated in the peritoneal fluid in one patient in the 
108-TCID
50
 cohort and two in the 109-TCID
50
 cohort, and in 
the serum in all three patients in the 109-TCID
50
 cohort. No 
antibody responses to MV-CEA were observed. This might 
have resulted from preexisting high baseline anti-measles 
antibody in enrolled patients who were required to be immu-
nized with measles for safety consideration in this first-ever 
human virotherapy trial with MV. Since MV predominantly 
utilizes the CD46 receptor for cell entry, the authors also 
examined the expression of CD46 in tumor specimens in 
15 patients whose tissues were available, attempting to 
investigate the effect of CD46 expression on the oncolytic 
activities of MV-CEA. Thirteen of the 15 patients showed 
high-level expression of CD46; however, no association of 
CD46 expression with clinical efficacy was observed. Due 
to the small patient sample size and different dosages used in 
this initial clinical trial, whether CD46 expression is associ-
ated with clinical efficacy remains to be identified.
Ad5-D24-GMCSF and Ad5/3-D24-
GMCSF
Two phase I clinical trials have been conducted to test 
whether GM-CSF could facilitate induction of antitumor 
immunity in the context of oncolytic Ad vectors Ad5-∆24 
and Ad5/3-∆24.188,189 Twenty patients with 15 different types 
of cancers (four patients with ovarian cancer) and 21 patients 
with twelve different types of cancers (four patients with 
ovarian cancer) were treated with Ad5-D24-GMCSF and 
Ad5/3-D24-GMCSF, separately. Viruses were administered 
using ultrasound-guided intratumoral injection or intracavity 
injection as in ovarian cancer patients, with one-fifth of the 
dose given IV. The starting dose of virus was 8 × 109 vp/d in 
the Ad5-D24-GMCSF trial, 8 × 1010 vp/d in the Ad5/3-D24-
GMCSF trial, and escalated to 4 × 1011 vp/d in both trials. 
Both studies showed that virus treatments were well tolerated 
and induced antitumoral and antiviral immune responses, as 
measured by the activation of tumor- and virus-specific cyto-
toxic T lymphocytes. Clinical benefits were also observed in 
some patients, including four patients with ovarian cancer 
in the Ad5-D24-GMCSF trial and one of four patients in the 
Ad5/3-D24-GMCSF trial.
JX-594
Taking the lead that VV has adapted to acquire stability in the 
bloodstream and is capable of rapid spread to distal tissues,191 
a phase I clinical trial was designed to test whether JX-594 
could target metastatic tumors via IV infusion.  Escalating 
dosages (1 × 105–3 × 107 pfu/kg) were administered in 
23 patients with nine different types of cancers, including 
two patients with recurrent ovarian cancer.187 Results from 
this study showed that JX-594 could selectively infect 
tumors after IV infusion in a dose-dependent manner. Viral 
infection of tumors was detected in all eight patients receiv-
ing the two highest doses of JX-594, but in only two out of 
15 patients receiving lower doses. Antitumor activities were 






also observed and appeared to be dose-dependent. One of 
the two patients with ovarian cancers receiving a lower dose 
of JX-594 was virus-negative in tumor but showed stable 
disease for more than 4 weeks after treatment. The other 
patient receiving the second- highest dose was virus-positive 
in the tumor and had stable disease for more than 16 weeks. 
The most common virus-associated adverse side effect was 
grade 1/2 flu-like symptoms, indicating that it is safe to 
administer JX-594 via this IV route.
GL-ONC1
GL-ONC1 (also named GLV-1h68) is an attenuated Lister 
strain VV with insertion of Renilla luciferase-GFP fusion 
gene, lacZ and β-glucuronidase reporter genes in the 
F14.5L, J2R (TK), and A56R (hemagglutinin) loci of the 
viral genome.192 This OV is being tested in a phase I/II trial 
in patients with advanced peritoneal cancers, which include 
ovarian cancer patients.193
Reolysin
The two ongoing Reolysin clinical trials are (1) a phase I trial 
in patients that did not respond to platinum chemotherapy, 
and (2) a phase II trial to investigate the safety and efficacy 
of Reolysin in combination with paclitaxel compared with a 
paclitaxel regime alone.194,195 In the first clinical trial, patients 
were treated with Reolysin via both IV and IP routes. Among 
the patients that have been treated, viral replication could be 
detected in peritoneal and ovarian cancer cells following IV 
administration.196 This is the first to reveal that reovirus can 
reach peritoneal and ovarian cancer via systemic delivery.
Conclusions
The use of live viruses specifically to kill cancer cells dates 
back as early as the beginning of the last century.197 However, 
the field of oncolytic virotherapy did not truly expand as 
a systematic inquiry until two decades ago, when genetic 
approaches were first applied to modify OVs in order spe-
cifically to target cancer cells.63,90 In 2005, Ad vector H101 
was approved in China as the world’s first approved OV 
for treatment of head and neck cancer in combination with 
chemotherapy.198 Currently two oncolytic viruses, Reolysin 
and OncoVEX, a herpex simplex type 1 virus–based onco-
lytic therapeutic agent, have entered pivotal phase III trials. 
JX-594 is also being tested in phase II clinical trials for liver 
cancer and metastatic colorectal cancer, and has shown great 
promise in preliminary results. Early last year, OncoVEX 
was acquired by Amgen in a deal that has been valued at up 
to US$1 billion. Although promising, we are still far from 
fulfilling the great potential of oncolytic virotherapy. One 
key challenge is our as-of-yet modest understanding of the 
multifactorial interactions between the tumor, its microen-
vironment, OVs, and the host immune responses to both the 
OV and the cancer cells.
Although preclinical and clinical studies have confirmed 
the safety and potential of OV therapy for ovarian cancer, 
many key outstanding questions remain to be addressed.
1.	 How can targeted delivery of OVs to ovarian tumor tis-
sue be improved? Preexisting antiviral antibodies and 
OV-induced immune responses to the virus can hinder 
the delivery of OVs to ovarian tumor sites. The carrier 
cell–based delivery strategy may overcome this hurdle, 
for example when tumor-homing MSCs are used to ferry 
virus to tumor tissues. The feasibility of this “Trojan 
horse” approach to virus delivery in the clinical setting 
remains to be tested.
2.	 What are the operative mechanisms for OV-mediated 
antiovarian cancer effects? The parameters that determine 
the susceptibility of individual ovarian cancer patients to 
virotherapy is still not clear in clinical settings. In addi-
tion, few studies have addressed the complex interactions 
between OVs and the various transformed and noncan-
cerous cells that inhabit all tumor microenvironments. 
Most importantly, the effects of residual or dysfunctional 
antitumor immunity and the immune-evasion strategies 
by ovarian carcinoma cells on the oncolytic efficacy have 
not been clearly elucidated. Numerous lines of evidence 
have indicated that host immunity acts as a “double-edged 
sword” in oncolytic virotherapy. On one hand, the rapid 
generation of host immune responses to the virus could 
preempt the time window for effective viral replication 
within the tumor bed. On the other hand, virus–tumor 
interactions can also liberate immune responses against 
tumor antigens and induce long-lasting bystander antitu-
mor immunity. A major unanswered question remains: 
does the direct killing of cancer cells by OVs or the 
virus-induced antitumor immunity play the major role in 
OV-induced cancer regression?
3.	 Can OVs target the more drug-resistant OCICs? The 
ability to target chemotherapy-resistant OCICs might 
determine the outcome of any new treatment for advanced 
ovarian cancer, particularly in combination with standard 
chemotherapies. So far, OVs have not been tested for their 
capability to infect and kill OCICs.
4.	 How can the oncolytic potency of OVs be improved? 
First, OVs in combination with chemotherapy have 
shown synergistic effects in treating ovarian cancer in 
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cell culture and animal models. Traditionally, OVs always 
enter clinical trials not as the first-line treatment but as a 
final-stage salvage attempt. Instituting earlier combination 
regimens of OVs with conventional therapeutics may be 
a far better strategy than testing OV monotherapy after 
standard treatments have already failed. Also, sequential 
employment of genetically different OVs for virotherapy 
has been shown be more effective to induce antitumor 
immunity in preclinical studies.139 This approach lever-
ages the observation that different OVs have very distinct 
tumor selectivities, which may facilitate targeting the cell 
heterogeneity associated with many cancers, including 
ovarian cancer.
5.	 Finally, preclinical studies have also indicated that 
many OVs can be armed with eff icacy-improving 
therapeutic genes. These adjunct genes can express 
immunoregulatory factors such as IL-12 and GM-CSF 
that can stimulate antitumor immunity by activating NK 
and CD8+ T cells. JX-594 and OncoVEX, being tested 
in clinical trials, are both armed with GM-CSF. It is 
worth noting that most current approaches aim to boost 
antitumor immune responses in cancer virotherapy by 
activating effector immune cells such as NK and CD8+ 
T cells. However, immunotherapy for cancer, particularly 
ovarian cancer, has increasingly focused on inhibiting 
regulatory T cells (Tregs) that block the development of 
effective T-cell immune responses to tumor antigens.199 
Circulating or tissue-resident Tregs may block effective 
antitumor immune responses in late-stage ovarian cancer, 
creating an effective immunosuppressive environment 
in the tumor. New strategies to combine OVs with Treg-
targeted suppression could be a key to achieve complete 
regression of patients with ovarian cancer. OVs are an 
ideal vehicle to deliver locally therapeutic gene products 
that could assist in mounting more effective cellular 
antitumor responses. Alternatively, OVs can be combined 
with drugs that inhibit Tregs, such as cyclophosphamide. 
In addition to its direct cytotoxic effect on cancer cells, 
gemcitabine has also been shown to eliminate Tregs selec-
tively, and preclinical models indicate that gemcitabine 
can synergize well with many OVs.
In many ways, the current state of oncolytic virotherapy is 
similar to the situation with the cytotoxic chemotherapy drugs 
first developed over half a century ago, with one notable 
exception. Like the older cytotoxic drugs still being used 
routinely in the clinic today, many OVs also exhibit potent 
anticancer properties in the preclinical setting, but there is 
a limit to what can be learned in animal models, and their 
correct exploitation in cancer patients now requires appropri-
ate clinical trials to teach oncologists how to exploit them 
effectively. In stark contrast to the classic chemotherapeutics 
that now comprise the standard of care for so many cancers, 
the single most notable characteristic of OV therapies tested 
to date is their extraordinary safety record. This should 
encourage the oncology field to be optimistic that exploiting 
the great potential of oncolytic virotherapy now needs to be 
conducted in the clinical arena. Despite the challenges ahead, 
advances in our understanding of tumorigenesis, antitumor 
immunity, and molecular biology and anticancer properties 
of OVs have helped and will continue to shape the transla-
tion of preclinical and clinical studies into significant clinical 
outcomes for cancer patients.
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